P115 Does trastuzumab increase ONJ development due to zoledronic acid treatment in breast cancer?

Abstract

had adjuvant therapy including tamoxifen. 3 of 13 patients (23%) who performed from total mastectomy, and 1 of 2 patient (50%) who performed from partial mastectomy had recurrence or metastasis (p = 0.229). After recurrence, they were treated from EC (epirubicin + cyclophosphamide), TC (docetaxel + cyclophosphamide), letrozole, or abraxane, and 3 of them are alive, 1 of them is unknown. Conclusion: It is suggested that tamoxifen treatment as adjuvant therapy may improve disease free survival. Almost all patients are estrogen receptor positive atmale breast cancer, therefore tamoxifen can be effective at male breast cancer therapy. Disclosure of Interest: No significant relationships.